期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 58, 期 34, 页码 11661-11665出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201903807
关键词
aptamers; aptamer-drug conjugates; drug combination cancer therapy; drug delivery; molecular engineering
资金
- NSFC [61527806, 21405041]
- State Key Laboratory of Chemo/Biosensing and Chemometrics
- Fundamental Research Funds for the Central Universities
Polytherapy (or drug combination cancer therapy (DCCT)), targeting multiple mechanisms associated with tumor proliferation, can efficiently maximize therapeutic efficacy, decrease drug dosage, and reduce drug resistance. However, most DCCT strategies cannot coordinate the specific delivery of a drug combination in an accurately tuned ratio into cancer cells. To address these limitations, the present work reports the engineering of circular bivalent aptamer-drug conjugates (cb-ApDCs). The cb-ApDCs exhibit high stability, specific recognition, excellent cellular uptake, and esterase-triggered release. Furthermore, the drug ratios in cb-ApDCs can be tuned for an enhanced synergistic effect without the need for complex chemistry. Therefore, cb-ApDCs provide a promising platform for the development of DCCT strategies for different drug combinations and ratios.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据